𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer

✍ Scribed by Joo Hyuk Sohn; Yong Wha Moon; Chang Geol Lee; Gwi Eon Kim; Kyung Young Chung; Joon Chang; Se Kyu Kim; Young Sam Kim; Byoung Wook Choi; Hye Jin Choi; Joo-Hang Kim

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
91 KB
Volume
109
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND.

A Phase II trial of irinotecan and cisplatin (IP) with early concurrent radiotherapy was performed in limited‐disease small‐cell lung cancer (LD‐SCLC) to evaluate the efficacy and toxicity.

METHODS.

For untreated LD‐SCLC patients, irinotecan (60 mg/m^2^, Days 1, 8, and 15) and cisplatin (40 mg/m^2^, Days 1 and 8) were repeated every 4 weeks for a maximum of 6 cycles. Thoracic radiotherapy of 1.8 Gy/day was begun on Day 1 of the second chemotherapy cycle, up to a total of 45 to 54 Gy. Prophylactic cranial irradiation (30 Gy in 10 fractions) was performed on patients with a complete response (CR).

RESULTS.

Thirty‐three LD‐SCLC patients were enrolled. The median age was 60 years and 31 patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Twelve (36.4%) patients had N3 disease. The response rate was 87.9%, with a CR rate of 45.5%. At a median follow‐up period of 27 months the median progression‐free survival (PFS) and overall survival (OS) were 14.4 and 26.1 months, respectively, with 2‐year PFS and OS rates of 26.8% and 54.9%. The dominating toxicity was neutropenia, with grade 3–5 of 81.8%. The most common grade 3–5 nonhematologic toxicities were diarrhea (21.2%), anorexia (21.2%), and fatigue (21.2%). Grade 3–5 radiation esophagitis and pneumonitis occurred in 18.2% and 9.1% of patients, respectively. There were 2 treatment‐related deaths from sepsis and radiation pneumonitis.

CONCLUSIONS.

IP with early concurrent radiotherapy was effective and tolerable in untreated LD‐SCLC. Cancer 2007. © 2007 American Cancer Society.

📜 SIMILAR VOLUMES

Phase II trial of irinotecan, cisplatin
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer
✍ Dean A. Fennell; Jeremy P.C. Steele; Jonathan Shamash; Sarah E. Slater; Michael 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 87 KB

## Abstract There is no standard therapy for relapsed small cell lung cancer (rSCLC). We evaluated the efficacy and toxicity of a new triplet consisting of irinotecan (100 mg/m^2^ Days 1 and 15 q28), cisplatin (40 mg/m^2^ Days 1 and 15 q28) and mitomycin (6 mg/m^2^ d1 q28) administered to a maximum

Irinotecan and cisplatin with concurrent
Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer : A multiinstitutional phase 2 study
✍ Minoru Fukuda; Hiroshi Soda; Masaaki Fukuda; Akitoshi Kinoshita; Yoichi Nakamura 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract ## BACKGROUND. The purpose was to determine the efficacy and toxicity of irinotecan and cisplatin with concurrent split‐course thoracic radiotherapy (TRT) in locally advanced nonsmall‐cell lung cancer. ## METHODS. Fifty patients fulfilling the following eligibility criteria were enro